|
Liposomal doxorubicin Clinical Trials
6 actively recruiting trials across 5 locations
Also known as: Caelyx, DOX, DOXIL®, Doxil®, Lipodox
Pipeline
Phase 1: 1Phase 2: 3Phase 3: 2
Top Sponsors
- Merck Sharp & Dohme LLC2
- Northwestern University1
- Memorial Sloan Kettering Cancer Center1
- Laura Huppert, MD, BA1
- H. Lee Moffitt Cancer Center and Research Institute1
Indications
- Cancer6
- Breast Cancer3
- Breast Neoplasms2
- Stage IIIC Breast Cancer1
- Stage IIIB Breast Cancer1
Birmingham, Alabama2 trials
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
O'Neal Comprehensive Cancer Center
Phase 2
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
University of Alabama at Birmingham (Children's of Alabama)
Phase 1
Daphne, Alabama1 trial
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Southern Cancer Center (SCC) ( Site 8000)
Phase 3
Chandler, Arizona1 trial
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ironwood Cancer & Research Centers ( Site 0066)
Phase 3
Miami, Florida1 trial
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
University of Miami
Phase 2
Chicago, Illinois1 trial
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Northwestern University
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.